http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PE-20181296-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D217-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D217-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-472 |
| filingDate | 2016-10-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c75563ca51915a0cf7465f4d33f3fc02 |
| publicationDate | 2018-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PE-20181296-A1 |
| titleOfInvention | CRYSTALLINE FORM OF 2- (2,6-DICHLOROPHENYL) -1 - [(1S, 3R) -3- (HYDROXIMETHYL) -5- (3-HYDROXY-3-METHYLBUTIL) -1-METHYL-3,4-DIHYDROISOQUINOLIN- 2 (1H) -IL] ETHANONE FOR THE TREATMENT OF PARKINSON'S DISEASE |
| abstract | Refers to a crystalline form of 2- (2,6-dichlorophenyl) -1 - [(1S, 3R) -3- (hydroxymethyl) -5- (3-hydroxy-3-methylbutyl) -1-methyl-3, 4-dihydroisoquinolin-2 (1H) -yl] ethanone and pharmaceutical compositions comprising said crystalline form. These compounds are positive allosteric modulators (MAP) of the dopamine 1 (D1) receptor and are useful for the treatment of Alzheimer's disease, Parkinson's disease, among others. |
| priorityDate | 2015-10-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 20.